Sana Biotechnology, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
3. Segment reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by thechief operating decision-maker (CODM), the Company's Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business inone operating segment. When evaluating the Company's financial performance, the CODM reviews total expenses and expenses by function. Further, the CODM reviews the segment's assets based on total assets reported on the consolidated balance sheet.
The table below is a summary of the segment loss, including significant segment expenses (in thousands):
| Three months ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| (in thousands) | ||
| Operating expenses: | ||
| Facility costs | $11,232 | $12,105 |
| Research and laboratory | 8,846 | 15,927 |
| Support functions | 8,654 | 13,645 |
| Technical operations and manufacturing | 7,436 | 10,023 |
| Stock-based compensation | 7,022 | 9,093 |
| Clinical development | 3,246 | 7,865 |
| Other(1) | 2,237 | 4,059 |
| Research and development related success payments and contingent consideration | 1,957 | 38,007 |
| Total operating expenses | 50,630 | 110,724 |
| Loss from operations | (50,630) | (110,724) |
| Interest income, net | 992 | 3,034 |
| Other income, net | 249 | 215 |
| Net loss | $(49,389) | $(107,475) |
(1) Other includes licensing costs, consulting fees, insurance and business taxes for the three months ended March 31, 2025 and 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.